CBIO Q3 2020 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M100.0% margin

Operating Income

-$14M-1372.7% margin

Net Income

-$14M-1372.3% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$150M

Total Liabilities

$12M

Stockholders' Equity

$138M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	-$70,783	+1512.8%
Operating Income	-$14M	-$14M	+2.7%
Net Income	-$14M	-$13M	-3.6%